Prolongation of survival of an allograft by inhibiting complement activity

Details for Australian Patent Application No. 2005244012 (hide)

Owner Alexion Pharmaceuticals, Inc.

Inventors Rother, Russell P.; Zhong, Zhen; Wang, Hao

Agent Shelston IP

Pub. Number AU-B-2005244012

PCT Pub. Number WO2005/110481

Priority 60/571,444 14.05.04 US

Filing date 16 May 2005

Wipo publication date 24 November 2005

Acceptance publication date 18 August 2011

International Classifications

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61M 5/28 (2006.01) Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle

Event Publications

7 December 2006 PCT application entered the National Phase

  PCT publication WO2005/110481 Priority application(s): WO2005/110481

20 March 2008 Alteration of Name

  The name of the applicant has been altered to Alexion Pharmaceuticals, Inc. 2006

18 August 2011 Application Accepted

  Published as AU-B-2005244012

15 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005244013-Compositions comprising ADDL receptor syngap

2005243988-Tungstic acid powder consisting of spherical tungsten particles and method for producing same